I

Inspire Medical Systems

FDA-approved neurostimulation device for OSA

Financial Analyst

Full-TimePosted on 10/15/2026
$70k - $88k+ Equity awards + Employee Stock Purchase Program
Junior, Mid
Bachelor's
Minneapolis, MN, USA
In Person
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A bachelor's degree in Finance, Accounting, Economics, Business Administration, or a related field is required.
  • A minimum of 1–2 years of experience in Financial Planning & Analysis (FP&A), corporate finance, accounting, business analysis, or a related finance function is required.
  • Strong analytical and financial modeling skills, including the ability to interpret complex data and provide actionable business recommendations, are required.
  • Proficiency in Microsoft Excel and PowerPoint is required.
  • The ability to manage multiple deadlines, coordinate deliverables across stakeholders, and communicate effectively with finance and business leaders is required.
Responsibilities
  • Build a deep understanding of the business, communicate results, and present recommendations to leadership team members.
  • Identify opportunities to improve and automate sales compensation systems to enhance efficiency and accuracy.
  • Answer managers’ questions about sales compensation plans, calculations, and payout structures.
  • Input data into sales compensation systems, ensuring accuracy and consistency across records.
  • Issue and track commission-related documents for commissionable employees and managers, and maintain commission plan templates and executed agreements.
  • Assist sales leadership and management with short- and long-term headcount planning, territory design, account alignment proposals, and identification of future expansion opportunities.
  • Collaborate cross-functionally and provide detailed sales analysis to support annual operating targets.
  • Compile data from multiple sources, perform variance and trend analysis, and build accurate tables, charts, and dashboards for stakeholder review.
  • Manage the quarterly sales forecasting process, identify and quantify forecast assumptions, highlight gaps, and help sales leaders understand and communicate needs.
  • Analyze sales and patient-flow trends, establish benchmarks for good and poor performance, and regularly highlight examples of both.
  • Document product- and therapy-related field reports within prescribed timelines and provide required documents to complete investigations; provide follow-up reporting as needed.
  • Complete required training and competency confirmations within the required timeline.
  • Comply with applicable quality-system procedures and policies and suggest continuous process improvements.
Desired Qualifications
  • Experience with ERP systems, financial planning tools, and business intelligence platforms is preferred.
  • Prior experience in a corporate or business FP&A team supporting sales is preferred.
  • Public company experience is preferred.
  • Experience with OneStream and Power BI is preferred.
  • Experience with SPFF is preferred.

About the company

I

Inspire Medical Systems

View

Inspire Medical Systems develops and sells a minimally invasive implantable device for obstructive sleep apnea (OSA). Its lead product, the Inspire system, uses implanted neurostimulation to activate the hypoglossal nerve, which moves the tongue and other airway muscles to keep the airway open during sleep. Patients control the therapy with a small handheld remote. The system targets adults with moderate to severe OSA who cannot use or benefit consistently from CPAP. Unlike non-implant options, Inspire provides a hands-free, on-demand airway support during sleep and is the first FDA-approved neurostimulation treatment for OSA. The company differentiates itself by offering a clinically approved implantable alternative to CPAP, backed by a direct US sales force and a network in Europe. Its goal is to provide an effective, durable option for patients who struggle with CPAP, expanding access to neurostimulation therapy to improve sleep quality and health outcomes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Golden Valley, Minnesota

Founded

2007

Get referred to Inspire Medical Systems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 Project Horizon targets $30 million annualized investment capacity by 2027.
  • September 2026 conference materials said coding clarity improved and WISeR-state billing issues eased.
  • CMS proposed 2027 facility-rate increases of 12% to 15%, supporting procedure economics.

What critics are saying

  • The January 2026 class action alleges Inspire V launch failures and misleading disclosures.
  • Medicare coding disruption cut second-quarter revenue $40 million; management expects $120 million-$130 million full-year impact.
  • If reimbursement stalls again before 2028 CPT approval, Inspire's growth thesis breaks quickly.

What makes Inspire Medical Systems unique

  • Inspire remains the only FDA-approved hypoglossal nerve stimulator for moderate-to-severe OSA.
  • The 2026 launch of Inspire V strengthened procedure simplicity and 3.0T MRI compatibility.
  • Direct U.S. sales and distributor coverage give Inspire tight control over adoption and education.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Unlimited Paid Time Off
  • Tuition Reimbursement
  • Employee Assistance program
  • Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 7th, 2026
Inspire Medical shares surge 28.1% after Q2 earnings beat and raised 2026 guidance

Inspire Medical Systems shares have risen 28.1% in the past month following a second-quarter earnings beat and raised 2026 guidance. The company reported adjusted earnings of 14 cents per share, surpassing consensus estimates for a 22-cent loss, whilst revenues of $200.6 million exceeded expectations despite declining 7.6% year over year. Management increased its 2026 revenue outlook to $835–875 million and raised adjusted earnings guidance to $1.05–$1.45 per share. The Zacks consensus estimate for 2026 earnings increased 34.7% over the past four weeks. However, coding challenges and prior authorisation programmes reduced second-quarter revenues by approximately $40 million. Management expects a full-year impact of $120–130 million and forecasts an 8–10% revenue decline in the third quarter.

Yahoo Finance
Aug 4th, 2026
Inspire Medical launches Project Horizon with $30M reinvestment to boost patient access amid reimbursement shifts

Inspire Medical Systems appointed AtriCure CEO Michael H. Carrel to its Board as director Casey M. Tansey plans to retire. The company reported quarterly revenue of $200.58 million and earnings of $0.14 per share, exceeding analyst expectations despite a year-on-year decline. Inspire raised its full-year outlook and launched Project Horizon, targeting $30 million in annualised investment capacity for patient access and education. The initiative comes alongside proposed reimbursement increases for its Inspire 5 procedure in 2027. The company's revenue narrative projects $987.4 million revenue and $67.1 million earnings by 2029. Investors are weighing the impact of Project Horizon against ongoing reimbursement and coding volatility affecting the firm's implant-based approach to obstructive sleep apnea treatment.

Yahoo Finance
Aug 3rd, 2026
Inspire Medical beats Q2 estimates with $200.6M revenue, raises full-year guidance to $855M

Inspire Medical Systems reported second-quarter revenue of $200.6 million, beating analyst estimates by 3% despite a 7.6% year-on-year decline. The medical technology company, which develops implantable devices for obstructive sleep apnea treatment, posted adjusted earnings per share of $0.14, significantly exceeding the consensus estimate of -$0.25. The company raised its full-year revenue guidance to $855 million at the midpoint, 1.4% above analyst expectations. Management also increased full-year adjusted EPS guidance to $1.25, a 25% rise. Adjusted EBITDA reached $38.9 million with a 19.4% margin, beating estimates by 40.5%. Following the results, Inspire Medical Systems' stock jumped 13.6%. CEO Tim Herbert attributed the performance to increased discipline whilst navigating evolving coding and reimbursement challenges.

Yahoo Finance
Aug 2nd, 2026
Inspire Medical Systems Q2 revenue expected to drop 10.3% year on year

Inspire Medical Systems will report Q2 earnings on Monday after the bell. The medical technology company is expected to see revenue decline 10.3% year on year, a reversal from the 10.8% increase recorded in the same quarter last year. Last quarter, Inspire Medical Systems reported revenues of $204.6 million, up 1.6% year on year, beating analysts' expectations. However, the company's full-year revenue and EPS guidance missed estimates significantly. Analysts have generally reconfirmed their estimates over the last 30 days. Inspire Medical Systems shares are up 3.6% over the past month, trading at $51.21 against an average analyst price target of $51.43. Peers Bausch + Lomb and Baxter recently beat Q2 revenue expectations, with shares rising 2.7% and 5.7% respectively following their results.